Your browser doesn't support javascript.
loading
Peppermint oil effects on the gut microbiome in children with functional abdominal pain.
Thapa, Santosh; Luna, Ruth Ann; Chumpitazi, Bruno P; Oezguen, Numan; Abdel-Rahman, Susan M; Garg, Uttam; Musaad, Salma; Versalovic, James; Kearns, Gregory L; Shulman, Robert J.
Afiliação
  • Thapa S; Department of Pathology, Texas Children's Microbiome Center, Texas Children's Hospital, Houston, Texas, USA.
  • Luna RA; Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas, USA.
  • Chumpitazi BP; Department of Pathology, Texas Children's Microbiome Center, Texas Children's Hospital, Houston, Texas, USA.
  • Oezguen N; Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas, USA.
  • Abdel-Rahman SM; Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas, USA.
  • Garg U; USDA/ARS Children's Nutrition Research Center, Texas Children's Hospital, Houston, Texas, USA.
  • Musaad S; Department of Pathology, Texas Children's Microbiome Center, Texas Children's Hospital, Houston, Texas, USA.
  • Versalovic J; Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas, USA.
  • Kearns GL; University of Missouri School of Medicine, Kansas City, Missouri, USA.
  • Shulman RJ; Department of Pathology and Laboratory Medicine, Children's Mercy Hospital, University of Missouri School of Medicine, Kansas City, Missouri, USA.
Clin Transl Sci ; 15(4): 1036-1049, 2022 04.
Article em En | MEDLINE | ID: mdl-35048535
Peppermint oil (PMO) is effective in the treatment of functional abdominal pain disorders, but its mechanism of action is unclear. Evidence suggests PMO has microbicidal activity. We investigated the effect of three different doses of PMO on gut microbiome composition. Thirty children (7-12 years of age) with functional abdominal pain provided a baseline stool sample prior to randomization to 180, 360, or 540 mg of enteric coated PMO (10 participants per dose). They took their respective dose of PMO (180 mg once, 180 mg twice, or 180 mg thrice daily) for 1 week, after which the stool collection was repeated. Baseline and post-PMO stools were analyzed for microbiome composition. There was no difference in alpha diversity of the gut microbiome between the baseline and post-PMO treatment. Principal coordinate analysis revealed no significant difference in overall bacterial composition between baseline and post-PMO samples, as well as between the PMO dose groups. However, the very low abundant Collinsella genus and three operational taxonomic units (one belonging to Collinsella) were significantly different in samples before and after PMO treatment. The Firmicutes/Bacteroidetes ratio was lower in children who received 540 mg of PMO compared to the 180 mg and 360 mg dose groups (p = 0.04). Network analysis revealed separation between pre- and post-PMO fecal samples with the genus Collinsella driving the post-PMO clusters. PMO administration appeared to impact only low abundance bacteria. The 540 mg PMO dose differentially impacted the Firmicutes/Bacteroidetes ratio. A higher dose and/or longer duration of treatment might yield different results.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Microbioma Gastrointestinal Tipo de estudo: Clinical_trials Idioma: En Revista: Clin Transl Sci Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Microbioma Gastrointestinal Tipo de estudo: Clinical_trials Idioma: En Revista: Clin Transl Sci Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos